Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457841 | 1.00 | FLT3 (0.53) | FLT3MAPTKCNH2ADORA3TNIK | |
| SCHEMBL5455183 | 0.87 | FLT3 (0.55) | FLT3MAPTKCNH2TNIKRAB9A | |
| SCHEMBL17006375 | 0.84 | KCNH2 (0.57) | FLT3MAPTKCNH2TNIKRAB9A | |
| SCHEMBL17018779 | 0.84 | KCNH2 (0.57) | FLT3MAPTKCNH2TNIKRAB9A | |
| SCHEMBL17006374 | 0.84 | KCNH2 (0.57) | FLT3MAPTKCNH2TNIKRAB9A | |
| SCHEMBL5455906 | 0.83 | FLT3 (0.74) | FLT3MAPTADORA3RAB9ATHRB | |
| SCHEMBL5453159 | 0.81 | FLT3 (0.55) | FLT3MAPTKCNH2TNIKRAB9A | |
| SCHEMBL5453424 | 0.80 | CFTR (0.59) | FLT3MAPTKCNH2RAB9ATHRB | |
| SCHEMBL5453529 | 0.79 | TNIK (0.59) | FLT3MAPTKCNH2TNIK | |
| SCHEMBL5451995 | 0.77 | FLT3 (0.51) | FLT3MAPTKCNH2TNIKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885MAPT 21/4885KCNH2 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.